Publication | Closed Access

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematologyPathologyImmunotherapyOncologyRadiation OncologyHealth Sciences